Thank You!
Thank you for your email subscription. Check your email to get Coupon Code.
Marketing Strategy for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships
Posted by Addison on Mar-29-2023
Introduction
The report primarily focuses on the marketing strategy of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to give a reader an overview of the growth dynamics of the company. Recently, several strategic issues and managerial problems have been identified in marketing strategy of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships that have drawn the attention of the entire management to devise new marketing strategies that can help the company to resolve the problems to continue its expansion and future growth to achieve a competitive edge in the marketplace. This report is written to provide GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships marketing strategy with the required strategic solutions using multiple frameworks and tools.
External Environmental Analysis
PESTLE Analysis is the most popular strategic tool that is used by many organizations when conducting an external environmental analysis. This framework typically focuses on political, economic, social, technological, legal, and environmental factors that can impact the macro environment of the business (Zalengera, E.Blanchard, & C.Eames, 2014).
Political factors
Political Stability
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in a politically stable environment, which means that it provides the company with more friendly and stable business growth opportunities (Christodoulou & Cullinane, 2019). However, since GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in multiple countries, there are high chances of various political tensions that can cause instability in market growth trends for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. This can limit the company's growth opportunities.
Pressure Groups
Moreover, it is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to analyze and monitor the activities of pressure groups. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can create a close collaboration with these groups to achieve long-term goals.
Corruption and Changing Policies
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships must keep a close check on the changes in any government policies because they can directly impact the performance of the business. The operations of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships are its different countries can become unpredictable if there is a high level of corruption and weak enforcement of the law (Achinas, Horjus, & Achinas, 2019).
Trade and Taxes
The profitability of a company is directly influenced if there are high taxes in a country. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should look into the taxation policies in each country before further expanding its operations (Eierle, Hartlieb, & C. Hay, 2022). Similarly, if there are high trade restrictions, it can get difficult for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to import and export its products, impacting the relationships with trade partners.
Economic factors
GDP, Employment, and Exchange Rates
The long-term growth strategies of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships are majorly determined by the GDP growth of the economy. The purchasing power of consumers significantly increases with a high GDP. High unemployment in an economy shows that GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can benefit from surplus labor with low-cost wages. Furthermore, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should monitor interest rates as it can affect the borrowing ability. With that being said, if there is a high fluctuation in currency, the profitability of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can also be influenced (Sadeghi, 2020).
Labor Market
It is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to make appropriate predictions regarding the labor market conditions in a specific economy (Sadeghi, 2020). This can help the company to hire a more talented workforce that can improve the performance of the company.
Industry lifecycle stage
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should consider expanding its operations in growing economies to benefit from growth opportunities. It can be challenging for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to enter a mature industry at a growing stage (Villamarín & Pinzon, 2017).
Social factors
Demographics
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should study the changing patterns of demographics, such as socio-economic variables, the aging population, and trends in migration (Barbara & Cortis, 2017). This can help the company to identify the right segment to target with a high potential for growth opportunities.
Cultural norms
Every country and society has a distinctive culture with different norms and values. It is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to study and identify social class stratification.
E-commerce
There has been a significant shift in online shopping. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships needs to adopt necessary changes considering the growing use of social media networking sites and mobile phones to increase its revenue and overall profitability (Villamarín & Pinzon, 2017).
Technological factors
Technological innovations
On-going technological innovations should be considered carefully by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships so that it can stay ahead of the competitive market. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should continue working on introducing major technological transformations to achieve a competitive advantage (Rastogi & TRIVEDI, 2016).
Social Media Marketing
The collaboration with consumers has been growing rapidly because of the development of communication technologies (Rastogi & TRIVEDI, 2016). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can take it as a great opportunity where can use innovative strategies to expand its customer base.
Environmental factors
Waste Management
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should implement the latest technological tools to minimize environmental pollution. Waste management is now getting popular and has been considered a major business norm (Igliński, Iglińska, & Cichosz, 2016).
Climatic Conditions and Eco-friendly products
Climatic conditions can influence the efficiency of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. The cost of a company's operations can be increased if there are extreme weather conditions. Similarly, there has been an increasing demand for eco-friendly products. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should work towards adopting more sustainable business practices to gain customer trust (Barkauskas, Barkauskienė, & Jasinskas, 2015).
Legal factors
Employee protection laws
It is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to follow the health and safety laws for its employees that are issued by the authorities to ensure the safety of its labor.
Consumer laws
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should protect its customer data to ensure their security and privacy concerns. Moreover, it should set the right price with the right product quality (Igliński, Iglińska, & Cichosz, 2016).
Porter's Five Forces
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can use Porter's Five Forces to analyze the competitive landscape of the industry. The strategic planners of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can use this framework to make effective decisions.
Threat of New Entrants
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in an industry where it is difficult to achieve economies of scale, making it difficult for new entrants to enter the industry (Yunna & Yisheng, 2014). There is a strong product differentiation with high capital requirements. Moreover, it is difficult to establish a distribution network easily in this industry. Thus, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has a weak threat of new entrants.
Bargaining Power of Suppliers
There are more suppliers in the industry of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. This shows that there is less control over prices. Organizations like GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can easily switch to other suppliers because of less differentiation in products. This makes the bargaining power of suppliers a weak force in GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships's industry (H. Th. Bruijl, 2018).
Bargaining Power of Buyers
The industry in which GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates has many suppliers as companies to buyers. This means that buyers have fewer options and do not have control over prices (H. Th. Bruijl, 2018). The high product differentiation shows that there are few alternative products for buyers, and there is a high switching cost. This makes the bargaining power of buyers a weak force in the industry.
Threat of Substitute Products and Services
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in an industry that offers very few substitutes to its customers. The substitutes that are available are expensive because of their high quality (Zhao, Zuo, & Wu, 2016). However, companies like GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships sell their products at a lower prices. This clearly shows that buyers may feel reluctant when switching to other substitutes.
Rivalry Among Existing Firms
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in a less competitive industry. The already established companies have a large market share, meaning that any move by the existing companies will be noticed. Moreover, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has to take several competitive actions to become a market leader, as the industry is likely to grow rapidly in the coming years (Aithal, 2020).
SWOT Analysis
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can make use of SWOT analysis to effectively analyze the company's internal strengths, weaknesses, external opportunities, and threats.
Strengths
Strong distribution network
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in various countries and has multiple outlets that help the company to deliver its products quickly to its customers. This shows that GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has a strong distribution network (Benzaghta, Elwalda, & Mousa, 2021).
Financial position
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has established itself as a strong financial company over the past few years. It has generated enough profits that can be used to finance any future expenditure (Basset & Mohamed, 2018).
Automation
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has adopted the latest and innovative technology in its business operations, which has allowed the company to reduce its production costs (Benzaghta, Elwalda, & Mousa, 2021).
Social media presence
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has been successful in establishing itself as a strong brand on social media platforms that, includes Facebook, Twitter, and Instagram. This increases customer engagement (Basset & Mohamed, 2018).
Weaknesses
High rent costs
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has its manufacturing plants on rented properties. This increases the company's overall costs, and a significant portion of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships's profits go into paying the rent (Comino & Ferretti, 2016).
Research and Development
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has not been able to conduct effective and in-depth market research regarding new markets and products (Comino & Ferretti, 2016). Customer trends are always evolving, and it is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to take immediate action in conducting its research.
Centralized Power
There has been a centralized decision-making process in GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. This means that employees have to consult their managers before taking any decision themselves. This slow down the decision-making process. and employees feel demotivated. Thus, impacting the operations of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships (Comino & Ferretti, 2016).
Opportunities
Presence of Internet
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has a great opportunity of expanding its business by using the internet. Since there has been a growing trend in online shopping GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can boost its sales by expanding its online stores (Yan, Xia, & X.H.Bao, 2015). Additionally, social media platforms can be updated constantly to engage customers with all the new products introduced by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships.
Technological Innovations
Technology is constantly evolving, and GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can benefit from it by implementing the technology in its various departments. Manufacturing process can be completed automated, which can eventually help GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to reduce its costs (Taghavifard, Mahdiraji, & Alibakhshi, 2018).
Globalization
The continuous increase in globalization has allowed GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to expand its business operations across borders. It has the opportunity of entering new markets (Yan, Xia, & X.H.Bao, 2015).
Threats
New Entrants
Recently, many companies are entering the industry in which GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates. This means that there are chances of increased competition. This poses a threat to GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships as it has to put more effort into gaining market share (Taghavifard, Mahdiraji, & Alibakhshi, 2018).
Fluctuations in exchange rates
The exchange rates are highly subjected to fluctuations that negatively impact the sales of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships needs to study the changing fluctuations to keep up with its profitability (Vlados & Chatzinikolaou, 2019).
Consumer trends
The consumer trends are constantly changing, that causes changes in their demands. This puts pressure on companies like GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships, who have to continuously meet their consumer demands. Moreover, there is a significant threat from substitute products because consumers tend to switch to these companies (Vlados & Chatzinikolaou, 2019).
Marketing Mix
Product
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in a wider range of products. Each of the products has its further product lines that are sold under the GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. This means that customers can benefit from a large variety of products. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships sells highly differentiated products with higher quality that, gives it a competitive edge (Khan, 2014).
Price
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships follows a competitive pricing strategy. The company also takes into account all its costs before setting its prices (Londhe, 2014). Currently, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships is using a product bundle pricing strategy where customers get bundled products at lower prices.
Place
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has adopted various distribution channels to reach its customers. The company sells its products through its website directly (Thabit & Raewf, 2018). Apart from this, it also distributes its products to wholesalers, who then further sell it to small retailers. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has its own retail stores where it sells its products directly to consumers.
Promotion
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships uses traditional and modern promotional techniques. TV ads are used to reach a larger audience. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships also advertises on social media sites such as Facebook, Instagram, and Twitter. Events are sponsored by the company. Moreover, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships participates in several exhibitions (Londhe, 2014).
VRIO Analysis
Valuable
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships engages in corporate social responsibility activities. This has allowed the company to establish a strong brand image. Since, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has a well-established distribution network, the products are reached to consumers in a timely manner. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has been able to introduce innovation in its various departments, which has lowered its costs (Ariyani & Daryanto, 2018).
Rare
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships operates in multiple countries. This means that its global presence is a rare factor. It works towards an organizational culture that encourages teamwork, and creativity among employees (Ariyani & Daryanto, 2018). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships is also able to adapt to different societies, and cultures due to its exposure to various locations.
Inimitable
The products produced by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships are of a high quality. Customers make repetitive purchases, and thus it is an inimitable source. (Miethlich & G. Oldenburg, 2019). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships has a significant placement of its stores that gives an easy access to its customers. Additionally, the company has been using a competitive pricing strategy because it has been able to achieve economies of scale, thus lower production costs.
Organization
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships, over the years, has successfully gained a financial strength. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can make use of these finances to invest in major acquisitions that give it more growth opportunities. The advancements in technology have allowed GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to manage its operations more effectively. Distribution channels are another resource for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. The supply chain is very efficient, resulting in more revenue (Miethlich & G. Oldenburg, 2019).
Value Chain Analysis
Primary Activities
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships is involved in primary activities such as the production of goods and then selling them to the target audience.
Inbound Logistics
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should ensure to have a strong relationship with its suppliers to avoid any inconvenience in receiving, storing, and distributing the product. This will help GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to have a more effective transformation of a product (Ariwibowo & Saputro, 2021).
Operations
Operations involves manufacturing as well as services. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should conduct an in-depth analysis of its operational activities to remain ahead of its competitors (M.El-Sayed, W.Dickson, & O.El-Naggar, 2015). This will increase the productivity of the company, and more profits can be generated.
Outbound Logistics
It is important for GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to analyze, and optimize its outbound logistics so that it is able to achieve the long-term corporate goals. Managing outbound activities properly reduces the chance of late deliveries (M.El-Sayed, W.Dickson, & O.El-Naggar, 2015).
Marketing and Sales
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should use various marketing and sales techniques to differentiate its products from its competitors. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can adopt marketing and sales activities such as promotional activities, advertising, and building strong relationships with suppliers and customers (Ariwibowo & Saputro, 2021).
Services
In terms of services, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships must ensure that it provides its customers with the pre-sale and post-sale services (Jaligot, C.Wilson, & R.Cheeseman, 2016). The post-sale service typically falls into the promotional activities of a company. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can thus develop its customer loyalty.
Secondary Activities
Firm infrastructure
A strong infrastructure of a firm can enable GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to optimize the entire value chain of the company. Moreover, by controlling the infrastructure activities, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can be in a better position to get a strong foothold in the competitive marketplace (Darmawan & Wiguna, 2014).
Human Resource Management
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should place its major focus on analyzing the different aspects of HR, such as recruitment, selection, training, and performance evaluation of employees (Darmawan & Wiguna, 2014). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can reduce its costs by identifying and analyzing the costs associated with hiring and training.
Procurement
Procurement is an important element in the GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships's value chain. It is important for the company to assess its overall procurement activities so that the inbound, outbound, and operational activities can be optimized (Kumar & P. V., 2016).
Ansoff's Matrix
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can implement Ansoff's Matrix to make decisions regarding its business growth. This framework includes four different strategic choices that can be selected by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships.
Market Penetration
Production capacity
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can increase its overall production capacity. This will allow the company to reach more wider audience in an existing market. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can also benefit from the reduced costs by expanding its production capacity. Thus, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can attract more customers using competitive pricing (Madsen, 2017).
Marketing Investment
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can penetrate the market by investing more in marketing and sales activities. This will help the company to engage with its customer more effectively, leading to more potential customers (Dawes, 2020).
Distribution Channels
Innovative and unique distribution channels can be explored by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. This will enable the company to reach new segments and groups of customers (Dawes, 2020). In addition to this, GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can penetrate the market by improving its supply chain, giving more accessibility to customers.
Joint Ventures/Acquisitions
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can enter into joint ventures or can take over other leading companies of the market. This will give GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships more market share.
Market Development
Research & Development
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should keep on investing in its R&D department, so it is able to identify the changing trends of the market. This will help GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to target the right market at the right time (Mukangai & Murigi, 2021).
Expanding Regionally
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can enter in a new market by expanding its operations regionally. This includes considering different cities of the country. GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships must consider any cultural differences when entering a new market (Mukangai & Murigi, 2021).
New Segments
New segments of the current market can be explored (Mukangai & Murigi, 2021). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can add new features and product uses to its existing products that satisfies the needs of a different customer segment.
Product Development
Modifications
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can modify the existing product by improving its features to enhance the product offerings.
Launching additional products
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships should invest in its R&D department so it can come up with new and innovative products that attracts and fulfill the needs of the target audience. This will boost the sales of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships and will increase profitability (Khajezadeh, Niasar, & Asli, 2019).
Diversification
Vertical Integration
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can consider vertical integration. This will allow GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to develop and launch new products that are similar to its existing product category (Khajezadeh, Niasar, & Asli, 2019).
Horizontal Integration
GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can diversify its business operation using horizontal integration. This means that the new products and services of GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships will not be related to its current products (Dhir & Dhir, 2015).
A new business diversification
Entering into a completely new business can be considered by GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships. The organization can work towards starting a new business that can give a company more growth prospects in the future (Dhir & Dhir, 2015). GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can conglomerate with the help of mergers and acquisitions.
Conclusion
To conclude, it could be said that GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can resolve its current managerial and strategic problems by focusing on its existing products. The company can adopt more attractive marketing strategies that can help GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships to boost its revenue and profitability. It is recommended to focus on maintaining strong supplier relationships. Moreover, it is also advised to focus on more innovative products so GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships can remain competitive in the market.
References
Achinas, S., Horjus, J., & Achinas, V. (2019). A PESTLE Analysis of Biofuels Energy Industry in Europe. Sustainability, 11(24), 5981.
Aithal, P. S. (2020). Study on GlaxoSmithKline in Brazil Public-Private Vaccine Partnerships Analysis Technique for Business Models, Business Strategies, Operating Concepts & Business Systems. International Journal in Management and Social Science, 95-115.
Ariwibowo, P., & Saputro, F. B. (2021). Analysis of Strength & Weakness, Using the Concept of Resource-Based View with the VRIO Framework in Sharia Cooperatives. Jurnal Manajemen Strategi Dan Aplikasi Bisnis, 279 - 294.
Ariyani, W., & Daryanto, A. (2018). Operationalization of Internal Analysis Using the VRIO Framework: Development of Scale for Resource and Capabilities Organization (Case Study: XYZ Company Animal Feed Business Unit). Asian Business Research Journal, 9–14.
Barbara, C., & Cortis, D. (2017). The European Insurance Industry: A PEST Analysis. International Journal of Financial Studies, 5(2), 14.
Barkauskas, V., Barkauskienė, K., & Jasinskas, E. (2015). Analysis of Macro Environmental Factors Influencing the Development of Rural Tourism: Lithuanian Case. Procedia - Social and Behavioral Sciences, 167-172.
Basset, M. A., & Mohamed, M. (2018). An Extension of Neutrosophic AHP–SWOT Analysis for Strategic Planning and Decision-Making. Symmetry, 10(4), 18.
Benzaghta, ,. M., Elwalda, A., & Mousa, M. M. (2021). SWOT analysis applications: An integr T analysis applications: An integrative literature review. Journal of Global Business Insights, 55-73.
Christodoulou, A., & Cullinane, K. (2019). Identifying the Main Opportunities and Challenges from the Implementation of a Port Energy Management System: A SWOT/PESTLE Analysis. Sustainability, 11(21), 6046.
Comino, E., & Ferretti, V. (2016). Indicators-based spatial SWOT analysis: Supporting the strategic planning and management of complex territorial systems. Ecological Indicators, 1104-1117.
Darmawan, M. A., & Wiguna, B. (2014). Value chain analysis for green productivity improvement in the natural rubber supply chain: a case study. Journal of Cleaner Production, 201-211.
Dawes, J. (2020). The Ansoff Matrix: A Legendary Tool, But with Two Logical Problems. SSRN.
Dhir, S., & Dhir, S. (2015). Diversification: Literature Review and Issues. Wiley Online Library.
Eierle, B., Hartlieb, S., & C. Hay, D. (2022). External Factors and the Pricing of Audit Services: A Systematic Review of the Archival Literature Using a PESTLE Analysis. A Journal of Practice & Theory, 95–119.
H. Th. Bruijl, D. G. (2018). The Relevance of Porter's Five Forces in Today's Innovative and Changing Business Environment. SSRN.
Igliński, B., Iglińska, A., & Cichosz, M. (2016). Renewable energy production in the Łódzkie Voivodeship. The PEST analysis of the RES in the voivodeship and in Poland. Renewable and Sustainable Energy Reviews, 737-750.
Jaligot, R., C.Wilson, D., & R.Cheeseman, C. (2016). Applying value chain analysis to informal sector recycling: A case study of the Zabaleen. Resources, Conservation and Recycling, 80-91.
Khajezadeh, M., Niasar, M. S., & Asli, S. A. (2019). Application of Neural Network in Portfolio Product Companies: Integration of Boston Consulting Group Matrix and Ansoff Matrix. International Journal of Economics and Management Engineering, 13(6), 809-813.
Khan, D. M. (2014). The Concept of ‘Marketing Mix’ and its Elements. International Journal of Information, Business and Management, 16(2), 95-107.
Kumar, D., & P. V., R. (2016). Value Chain: A Conceptual Framework. International Jorunal of Engineering and Management Sciences, 74-77.
Londhe, B. (2014). Marketing Mix for Next Generation Marketing. Procedia Economics and Finance, 335-340.
M.El-Sayed, A.-F., W.Dickson, M., & O.El-Naggar, G. (2015). Value chain analysis of the aquaculture feed sector in Egypt. Aquaculture, 92-101.
Madsen, D. Ø. (2017). Not Dead Yet: The Rise, Fall and Persistence of the BCG Matrix. Problems and Perspectives in Management, 19-34 .
Miethlich, B., & G. Oldenburg, A. (2019). The Employment of Persons with Disabilities as a Strategic Asset: A Resource-Based-View using the Value-Rarity-Imitability-Organization (VRIO) Framework. Journal of Eastern Europe Research in Business and Economics, 1-13.
Mukangai, W. I., & Murigi, E. M. (2021). The Effect of Market Development on Sales Performance of Agro-Based Dealers in Nairobi City County, Kenya. Journal of Marketing and Communication, 4(1), 23-35.
Rastogi, N., & TRIVEDI, D. (2016). Pestle Technique- A Tool to Identify External Risks in Construction Projects. International Research Journal of Engineering and Technology, 3(1), 385-388.
Sadeghi, V. a. (2020). The motivational factors of business venturing: Opportunity versus necessity? A gendered perspective on European countries. Journal of Business Research, 279-289.
Taghavifard, M. T., Mahdiraji, H. A., & Alibakhshi, A. M. (2018). An Extension of Fuzzy SWOT Analysis: An Application to Information Technology. Information, 9(3), 46.
Thabit, T., & Raewf, M. (2018). The Evaluation of Marketing Mix Elements: A Case Study. International Journal of Social Sciences & Educational Studies, 4(4), 100 - 109.
Villamarín, J. M., & Pinzon, B. D. (2017). Key Success Factors to Business Intelligence Solution Implementation. Journal of Intelligence Studies in Business, 48-69.
Vlados, C., & Chatzinikolaou, D. (2019). Towards a Restructuration of the Conventional SWOT Analysis. Business and Management Studies, 76-84.
Yan, J., Xia, F., & X.H.Bao, H. (2015). Strategic planning framework for land consolidation in China: A top-level design based on SWOT analysis. Habitat International, 46-54.
Yunna, W., & Yisheng, Y. (2014). The competition situation analysis of shale gas industry in China: Applying Porter’s five forces and scenario model. Renewable and Sustainable Energy Reviews, 798-805.
Zalengera, C., E.Blanchard, R., & C.Eames, P. (2014). Overview of the Malawi energy situation and A PESTLE analysis for sustainable development of renewable energy. Renewable and Sustainable Energy Reviews, 335-347.
Zhao, Z. Y., Zuo, J., & Wu, P. H. (2016). Competitiveness assessment of the biomass power generation industry in China: A five forces model study. Renewable Energy, 144-153.
Related Article
- PESTEL Analysis of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- Hofstede Cultural Model of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- Net Present Value (NPV) Analysis of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- Marketing Mix (4Ps) Analysis of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- Corporate Social Responsibility of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- GlaxoSmithKline in Brazil Public Private Vaccine Partnerships Discounted Cash Flow (DCF) Analysis
- VRIO Analysis of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
- GlaxoSmithKline in Brazil Public Private Vaccine Partnerships Case Solution
- Blue Ocean Strategy of GlaxoSmithKline in Brazil Public Private Vaccine Partnerships
Latest Feedback
Zoe Ryan
Verified
I decided to try this service for the report writing and it proved an awesome company for the assignment. I'm grateful for this. Thanks!
Lin Zhao
Verified
I’ve just hired this service for the third time because my two earlier papers were under the requirements of the teacher.
Ilan Ludovic
Verified
Editing and proofreading work was top-notch. As always outstanding and the paper was completed on time. Awesome customer service!
Abegail Gavino
Verified
I left the half-semester due to illness so to compose a report was a time-taking and stiff process for me. My friend suggested this service and I hired this. Thank you because the paper is excellent!
James Theodore
Verified
Extremely quick turnaround and no evidence of plagiarism. I would like to refer to this service.
Zsofi Mark
Verified
The assignment was without even an irrelevant sentence. The construction of words was suitable. Thanks!
Calculate the Price of Your Order
Next Article
- Brief Biographical Note on P. Roy Vagelos Marketing Strategy
- CIBA Vision: The EUROLOGISTICS Initiative Marketing Strategy
- Medicines for Malaria Venture: Accessing the Inaccessible! Marketing Strategy
- GLAXOSMITHKLINE AND AIDS DRUGS IN SOUTH AFRICA (B): THE SETTLEMENT Marketing Strategy
- Finance Leadership in Novartis Consumer Health Businesses Marketing Strategy
- Antegren: A Beacon of Hope (B), Chinese Version Marketing Strategy
- Hans Fritz at Novartis Thailand (C) Marketing Strategy
- Laura Esserman -- Paths to Power (Part 2), (Video) DVD Marketing Strategy
- Socially Responsible Pricing: Lessons from the Pricing of AIDS Drugs in Developing Countries Marketing Strategy
- Treu Pharma: Role for Alex Hoffman Marketing Strategy
Previuos Article
- Making the Case Marketing Strategy
- Joe Smith's Closing Analysis (B) Marketing Strategy
- Joe Smith's Closing Analysis (A), Spanish Version Marketing Strategy
- GMAC: The Pipeline Marketing Strategy
- On Writing Teaching Notes Well Marketing Strategy
- Exxon Corp.: Trouble at Valdez Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (A) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (B) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (C) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (D) Marketing Strategy
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire EssayPandas with BIG enough reputation.
Our Guarantees
- Quality assured
- Proof of no plagiarism
- Qualified writers
- Data security
- 24/7 support
- On time delivery
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!
Order Now